Form 4: Axsome Therapeutics Director Saad Acquires Stock Options in Lieu of Cash Compensation

Director Mark E. Saad of Axsome Therapeutics acquired 1,494 stock options in lieu of cash compensation on February 21, 2025.

Summary

• On February 21, 2025, Mark E. Saad, a director of Axsome Therapeutics, acquired 1,494 stock options.
• These options were received in lieu of cash compensation earned in 2024.
• The exercise price of the options is $137.75.
• The options are immediately exercisable and expire on February 20, 2035.
• Following the transaction, Saad directly owns 1,494 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and aligns the director's interests with shareholders. There are no explicit negative implications.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The options being immediately exercisable provides flexibility for the director.

Industry Context

This is a standard practice for compensating directors and aligning their interests with those of the shareholders. Stock options incentivize directors to work towards increasing the company's stock value.

Comparison to Industry Standards

• Granting stock options to directors as part of their compensation is a common practice across the pharmaceutical and biotechnology industries.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options as a component of director compensation packages.
• The specific number of options granted and the exercise price are typically determined based on factors such as the director's role, experience, and the company's performance.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates